In conclusion, the discovery of the mechanisms through which fibrotic signaling promotes tumorigenesis and aggressiveness in RCC provides inspiration for the development of anti-fibrotic therapies, such as mTOR inhibitors or anti-TGF-β antibodies, as novel therapeutic strategies for renal cancer. Here, MTOR is linked to renal cell carcinoma.